Ranbaxy recalls antibiotic drug from US market

April 15, 2010 03:39 pm | Updated April 16, 2010 12:24 pm IST - New Delhi

Ranbaxy Laboratories on Thursday said its US subsidiary is voluntarily recalling two lots of an antibiotic drug from the American market after receiving certain complaints about them.

The company’s US arm, Ranbaxy Pharmaceuticals Inc is conducting the recall after receiving a limited number of complaints about the drug, which is in powdered form, changing colours when mixed with water to make formulations.

“Ranbaxy Pharmaceuticals Inc., Jacksonville, Florida is conducting a voluntary recall of Amoxicillin and Clavulanate Potassium for Oral Suspension, which is limited to Lot No 1910779 and 1910782 with expiry of May 2010 that is currently available in the US market,” Ranbaxy Laboratories said in a statement.

Based on a limited number of complaints from the US market that describe a change in colour of the product on reconstitution, the company has decided to recall all the lots in question as a matter of caution, given its commitment to the health and safety of patients, it added.

The recall is being carried out at the retail level and is being conducted with the full knowledge of the US health regulator Food and Drug Administration (FDA), it said.

The company, however, declined to comment on the impact of the recall on its earnings, but according to industry experts, “it will be negligible.”

Earlier in July last year, on recommendations of the US FDA, Ranbaxy had recalled a single lot of Sotret Isotretinoin capsules in 40 mg strength, used in the treatment of acne (a type of skin disease) from the US market.

Ranbaxy had got the USFDA nod to market the drug in 2003 and it has annual sales of around USD 415 million in the US.

The Gurgaon-based company is yet to sort out issues with the US FDA regarding good manufacturing-practices compliance of its two units located in Dewas, Madhya Pradesh and Paonta Sahib, Himachal Pradesh.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.